Indian pharmaceutical company Hetero today launched generic oral antivirual drug Favipiravir used for the treatment of patients with mild to moderate Covid-19, under the brand name ‘Favivir’ at Rs 59 per tablet. Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).
According to the manufacturers, Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. ‘It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid 19 patient population, which usually sustains mild to moderate symptoms” Hetero said in a statement.
Hetero’s Favivir will be marketed and distributed by Hetero Healthcare Limited. The product is available from 29th July onwards at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.
CLICK HERE !! To be found on google search engine